This, together with previous in-vivo studies demonstrating greater tumor regression of xenografts of MIP/SP cells to chemotherapy [4] led us to examine if tumor xenografts overexpressing the N-terminus domain of SPARC also had a heightened sensitivity to chemotherapy. The gene discussed is SPARC; the disease is neoplasm.